# COL2A1

## Overview
The COL2A1 gene encodes the collagen type II alpha 1 chain, a fibrillar collagen protein that plays a critical role in the structural integrity of cartilage. This protein is a major component of the extracellular matrix in articular cartilage, where it forms a fibrous network that provides tensile strength and supports the tissue's resilience. The collagen type II alpha 1 chain is characterized by its triple-helical structure, which is stabilized by a repeating Gly-X-Y sequence, essential for its function in connective tissues. The expression of COL2A1 is tightly regulated during cartilage development and is crucial for maintaining the differentiated phenotype of chondrocytes, the cells responsible for synthesizing cartilage matrix components. Mutations in the COL2A1 gene are associated with a spectrum of disorders known as type II collagenopathies, which include conditions such as achondrogenesis type II, spondyloepiphyseal dysplasia congenita, and Stickler syndrome, each varying in severity and clinical presentation (Hoornaert2010Stickler; Ghayor2000Regulation; BaratHouari2015Mutation).

## Structure
The COL2A1 gene encodes the alpha-1 chain of type II collagen, a fibrillar collagen primarily found in cartilage. The primary structure of this protein is characterized by a repeating Gly-X-Y sequence, where glycine is essential for the tight packing of the helix, and X and Y are often proline and hydroxyproline (Bruni2021A; BaratHouari2015Mutation). The secondary structure forms a triple helix, which is a hallmark of collagen proteins, providing tensile strength to connective tissues (Zhang2019Integrated; BaratHouari2015Mutation).

The tertiary structure involves the formation of a homotrimeric structure, where three identical alpha-1 chains twist together to form a triple-helical domain (Zhang2019Integrated). This domain is stabilized by about 300 Gly-X-Y repeats, which are critical for the stability of collagen (Zhang2019Integrated). The quaternary structure involves the assembly of these homotrimers into a fibrillar network in the extracellular matrix (Zhang2019Integrated).

Post-translational modifications include hydroxylation and glycosylation, which are important for the proper assembly and function of the collagen fibrils (McAlinden2014Molecular). The COL2A1 gene also undergoes alternative splicing, resulting in different isoforms, such as IIA and IIB, which are expressed at different stages of chondrocyte differentiation (Hering2014Changes; McAlinden2008Expression).

## Function
The COL2A1 gene encodes the alpha-1 chain of type II collagen, a fibrillar collagen primarily found in cartilage. This protein is a crucial component of the extracellular matrix in articular cartilage, where it forms an insoluble fibrous network that provides tensile strength and structural integrity to the tissue (Ghayor2000Regulation). Type II collagen is secreted by differentiated chondrocytes as a procollagen molecule, which is then processed into collagen molecules that self-assemble into fibrils. These fibrils serve as scaffolding for proteoglycans in cartilage, contributing to the tissue's resilience and function (Rani1999Restoration).

The expression of COL2A1 is tightly regulated during cartilage development, differentiation, and repair. It is essential for maintaining the differentiated phenotype of chondrocytes, which are the cells responsible for synthesizing cartilage matrix components (Ghayor2000Regulation; Lafont2016Hypoxia). The transcription factor SOX9 plays a significant role in activating the chondrocyte-specific enhancer of the COL2A1 gene, ensuring its expression in chondrogenic cells (Lefebvre1997SOX9). This regulation is crucial for proper skeletal development and joint function, as type II collagen is a major structural protein in the cartilage matrix (Rani1999Restoration).

## Clinical Significance
Mutations in the COL2A1 gene, which encodes the alpha-1 chain of type II collagen, are associated with a group of disorders known as type II collagenopathies. These conditions exhibit a wide range of clinical manifestations, from severe to mild phenotypes. Severe conditions include achondrogenesis type II and hypochondrogenesis, which are often lethal in the perinatal period and characterized by incomplete bone ossification and skeletal abnormalities (&lt; p&gt; em&gt; COL2A1&lt; Nenna2019&lt; BaratHouari2015Mutation). Intermediate severity phenotypes include spondyloepiphyseal dysplasia congenita (SEDC) and Kniest dysplasia, which involve short stature, joint enlargement, and ocular defects (Hoornaert2010Stickler; BaratHouari2015Mutation). Milder forms, such as Stickler syndrome type I, are characterized by ocular, orofacial, auditory, and skeletal manifestations, including congenital myopia and a high risk of retinal detachments (Nagendran2012Somatic; Hoornaert2010Stickler).

The mutations in COL2A1 often occur in the triple helix region, particularly involving glycine substitutions, which disrupt collagen stability and function (BaratHouari2015Mutation). These mutations can lead to dominant-negative effects or haploinsufficiency, affecting the stability and function of type II collagen (&lt; p&gt; em&gt; COL2A1&lt; Nenna2019&lt). The phenotypic variability is influenced by the specific mutation and its location within the gene, as well as environmental factors and polymorphisms in other genes (Zhang2019Integrated).

## Interactions
The COL2A1 gene, encoding the collagen type II alpha 1 chain, is involved in several interactions with proteins and nucleic acids that regulate its expression and function. The nuclear protein TIA-1 plays a significant role in the alternative splicing of COL2A1 by binding to a U-rich region within a stem-loop cis element in the precursor mRNA. This interaction promotes the inclusion of exon 2, crucial for producing the type IIA isoform during chondrogenesis (McAlinden2007Nuclear). TIA-1 also binds to an AU-rich cis element in the COL2A1 pre-mRNA and an equivalent AT-rich element in the genomic DNA, suggesting a dual role in co-regulating transcription and pre-mRNA splicing (McAlinden2007Nuclear).

Notch signaling proteins HES-1 and HEY-1 interact with the COL2A1 enhancer site, specifically binding to N-box domains in intron 1. This binding recruits corepressor proteins, forming a complex that represses transcription by blocking the SOX9 enhancer site, which is essential for COL2A1 activation. The presence of TGFβ3 can dismiss these repressors, allowing transcription and chondrogenesis to proceed (Grogan2008Repression). These interactions highlight the complex regulatory mechanisms controlling COL2A1 expression during cartilage development.


## References


[1. (McAlinden2007Nuclear) Audrey McAlinden, Li Liang, Yoshiki Mukudai, Toshihiro Imamura, and Linda J. Sandell. Nuclear protein tia-1 regulates col2a1 alternative splicing and interacts with precursor mrna and genomic dna. Journal of Biological Chemistry, 282(33):24444–24454, August 2007. URL: http://dx.doi.org/10.1074/jbc.M702717200, doi:10.1074/jbc.m702717200. This article has 54 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M702717200)

[2. (Bruni2021A) Valentina Bruni, Cristina Barbara Spoleti, Andrea La Barbera, Vincenzo Dattilo, Emma Colao, Carmela Votino, Emanuele Bellacchio, Nicola Perrotti, Sabrina Giglio, and Rodolfo Iuliano. A novel splicing variant of col2a1 in a fetus with achondrogenesis type ii: interpretation of pathogenicity of in-frame deletions. Genes, 12(9):1395, September 2021. URL: http://dx.doi.org/10.3390/genes12091395, doi:10.3390/genes12091395. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes12091395)

[3. (Nagendran2012Somatic) Sonali Nagendran, Allan J. Richards, Annie McNinch, Richard N. Sandford, and Martin P. Snead. Somatic mosaicism and the phenotypic expression of col2a1 mutations. American Journal of Medical Genetics Part A, 158A(5):1204–1207, April 2012. URL: http://dx.doi.org/10.1002/ajmg.a.35303, doi:10.1002/ajmg.a.35303. This article has 31 citations.](https://doi.org/10.1002/ajmg.a.35303)

[4. (Rani1999Restoration) Pyapalli U. Rani, Emanuela Stringa, Rita Dharmavaram, Devjani Chatterjee, Rocky S. Tuan, and Jaspal S. Khillan. Restoration of normal bone development by human homologue of collagen type ii (col2a1) gene in col2a1 null mice. Developmental Dynamics, 214(1):26–33, January 1999. URL: http://dx.doi.org/10.1002/(SICI)1097-0177(199901)214:1<26::AID-DVDY3>3.0.CO;2-V, doi:10.1002/(sici)1097-0177(199901)214:1<26::aid-dvdy3>3.0.co;2-v. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/(SICI)1097-0177(199901)214:1)

[5. (Ghayor2000Regulation) C. Ghayor. Regulation of human col2a1 gene expression in chondrocytes: identification of c-krox responsive elements and modulation by phenotype alteration. Journal of Biological Chemistry, June 2000. URL: http://dx.doi.org/10.1074/jbc.m002139200, doi:10.1074/jbc.m002139200. This article has 2 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m002139200)

[6. (BaratHouari2015Mutation) Mouna Barat-Houari, Guillaume Sarrabay, Vincent Gatinois, Aurélie Fabre, Bruno Dumont, David Genevieve, and Isabelle Touitou. Mutation update forcol2a1gene variants associated with type ii collagenopathies: human mutation. Human Mutation, 37(1):7–15, October 2015. URL: http://dx.doi.org/10.1002/humu.22915, doi:10.1002/humu.22915. This article has 100 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.22915)

[7. (McAlinden2014Molecular) Audrey McAlinden, Geoffrey Traeger, Uwe Hansen, Mary Ann Weis, Soumya Ravindran, Louisa Wirthlin, David R. Eyre, and Russell J. Fernandes. Molecular properties and fibril ultrastructure of types ii and xi collagens in cartilage of mice expressing exclusively the α1(iia) collagen isoform. Matrix Biology, 34:105–113, February 2014. URL: http://dx.doi.org/10.1016/j.matbio.2013.09.006, doi:10.1016/j.matbio.2013.09.006. This article has 27 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.matbio.2013.09.006)

[8. (Hering2014Changes) Thomas M. Hering, Louisa Wirthlin, Soumya Ravindran, and Audrey McAlinden. Changes in type ii procollagen isoform expression during chondrogenesis by disruption of an alternative 5′ splice site within col2a1 exon 2. Matrix Biology, 36:51–63, June 2014. URL: http://dx.doi.org/10.1016/j.matbio.2014.04.004, doi:10.1016/j.matbio.2014.04.004. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.matbio.2014.04.004)

[9. (Zhang2019Integrated) Boyan Zhang, Yue Zhang, Naichao Wu, Jianing Li, He Liu, and Jincheng Wang. Integrated analysis of col2a1 variant data and classification of type ii collagenopathies. Clinical Genetics, 97(3):383–395, December 2019. URL: http://dx.doi.org/10.1111/cge.13680, doi:10.1111/cge.13680. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/cge.13680)

[10. (Lafont2016Hypoxia) J.E. Lafont, F.-A. Poujade, M. Pasdeloup, P. Neyret, and F. Mallein-Gerin. Hypoxia potentiates the bmp-2 driven col2a1 stimulation in human articular chondrocytes via p38 mapk. Osteoarthritis and Cartilage, 24(5):856–867, May 2016. URL: http://dx.doi.org/10.1016/j.joca.2015.11.017, doi:10.1016/j.joca.2015.11.017. This article has 28 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.joca.2015.11.017)

[11. (Hoornaert2010Stickler) Kristien P Hoornaert, Inge Vereecke, Chantal Dewinter, Thomas Rosenberg, Frits A Beemer, Jules G Leroy, Laila Bendix, Erik Björck, Maryse Bonduelle, Odile Boute, Valerie Cormier-Daire, Christine De Die-Smulders, Anne Dieux-Coeslier, Hélène Dollfus, Mariet Elting, Andrew Green, Veronica I Guerci, Raoul C M Hennekam, Yvonne Hilhorts-Hofstee, Muriel Holder, Carel Hoyng, Kristi J Jones, Dragana Josifova, Ilkka Kaitila, Suzanne Kjaergaard, Yolande H Kroes, Kristina Lagerstedt, Melissa Lees, Martine LeMerrer, Cinzia Magnani, Carlo Marcelis, Loreto Martorell, Michèle Mathieu, Meriel McEntagart, Angela Mendicino, Jenny Morton, Gabrielli Orazio, Véronique Paquis, Orit Reish, Kalle O J Simola, Sarah F Smithson, Karen I Temple, Elisabeth Van Aken, Yolande Van Bever, Jenneke van den Ende, Johanna M Van Hagen, Leopoldo Zelante, Riina Zordania, Anne De Paepe, Bart P Leroy, Marc De Buyzere, Paul J Coucke, and Geert R Mortier. Stickler syndrome caused by col2a1 mutations: genotype–phenotype correlation in a series of 100 patients. European Journal of Human Genetics, 18(8):872–880, February 2010. URL: http://dx.doi.org/10.1038/ejhg.2010.23, doi:10.1038/ejhg.2010.23. This article has 111 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2010.23)

[12. (McAlinden2008Expression) Audrey McAlinden, Brian Johnstone, John Kollar, Najam Kazmi, and Thomas M. Hering. Expression of two novel alternatively spliced col2a1 isoforms during chondrocyte differentiation. Matrix Biology, 27(3):254–266, April 2008. URL: http://dx.doi.org/10.1016/j.matbio.2007.10.002, doi:10.1016/j.matbio.2007.10.002. This article has 37 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.matbio.2007.10.002)

[13. (Lefebvre1997SOX9) Véronique Lefebvre, Wendong Huang, Vincent R. Harley, Peter N. Goodfellow, and Benoit de Crombrugghe. Sox9 is a potent activator of the chondrocyte-specific enhancer of the proα1(ii) collagen gene. Molecular and Cellular Biology, 17(4):2336–2346, April 1997. URL: http://dx.doi.org/10.1128/mcb.17.4.2336, doi:10.1128/mcb.17.4.2336. This article has 880 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.17.4.2336)

[14. (Grogan2008Repression) Shawn P. Grogan, Tsaiwei Olee, Koji Hiraoka, and Martin K. Lotz. Repression of chondrogenesis through binding of notch signaling proteins hes‐1 and hey‐1 to n‐box domains in the col2a1 enhancer site. Arthritis &amp; Rheumatism, 58(9):2754–2763, August 2008. URL: http://dx.doi.org/10.1002/art.23730, doi:10.1002/art.23730. This article has 73 citations.](https://doi.org/10.1002/art.23730)